Nadh and nadph as drugs for treating alzheimer's disease
CA 2105912 C · Owner: Birkmayer, Jorg · Inventors: Birkmayer, Jorg
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Use of the reduced form of nicotinamide adenine dinucleotide (NADH), the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), or a physiologically compatible salt thereof for the treatment of Alzheimer's disease is disclosed. Also disclosed is a composition for the treatment of Alzheimer's disease. The composition comprises NADH NADPH or a physiologically, compatible salt thereof and a pharmaceutically acceptable carrier.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 10, 1993 and granted November 14, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 10, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 10, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.